Surgery Partners Trims 2025 Guidance After Q3 EPS Miss, Shares Fall

A reduced full-year outlook overshadowed in-line revenue to drive a sharp selloff.

Overview

Third-quarter revenue rose 6.6% year over year to $821.5 million, landing essentially in line with Wall Street estimates.
Adjusted earnings per share were $0.13, below the roughly $0.16 analyst consensus.
Management cut full-year 2025 guidance to $3.275–$3.30 billion in revenue and $535–$540 million in adjusted EBITDA.
Shares dropped sharply following the report and outlook reduction, reflecting investor focus on the weaker forecast.
Operational metrics improved, with operating margin up to 12.9% from 7.9% and free cash flow margin up to 7.8% from 5.8%.